Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cobra cytotoxins (CTXs), also widely known as cardiotoxins, are a major group of non-enzymatic proteins found in the venom of cobras, particularly those in the Naja genus. They belong to the three-finger toxin (3FTx) superfamily, characterized by a conserved structural motif of three beta-sheet loops extending from a central hydrophobic core stabilized by four disulfide bonds [1][2]. These toxins primarily function by binding to anionic phospholipids in the plasma membrane, leading to membrane pore formation, loss of cellular integrity, and subsequent necrosis or apoptosis [2][4]. In the context of snakebite envenomation, CTXs are the primary agents responsible for extensive local tissue destruction and can contribute to systemic effects such as cardiovascular failure and hemolysis [3][5]. From a therapeutic perspective, they are the critical targets for neutralization by antivenom antibodies, which prevent the toxins from docking onto host cell membranes. Furthermore, their potent and sometimes selective cytotoxic properties have led to significant research interest in their potential application as anti-tumor agents in oncology [4][5]. Sources: [1] UniProt Consortium. "Cytotoxin 1 - Naja atra (Chinese cobra)." [2] Dubovskii, P. V., et al. (2014). "Cobra cytotoxins: structural organization and membrane interactions." Toxins. [3] World Health Organization (WHO). "Guidelines for the Production, Control and Regulation of Snake Antivenom Sera." [4] Gasanov, S. E., et al. (2014). "Cobra venom cytotoxins; structural biology and cellular toxicity." Archives of Toxicology. [5] PubMed Central. "Mechanism of action of cobra venom cardiotoxins."
Therapeutic antibodies in antivenom bind to the three-finger loops of the cytotoxin, sterically hindering its ability to interact with and insert into the host cell membrane phospholipids, thereby neutralizing its lytic activity [1][3].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cobra cytotoxin (CTX).